Literature DB >> 31443071

Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications.

Joshua D Bernstock1,2, James H Mooney1, Adeel Ilyas1, Gustavo Chagoya1, Dagoberto Estevez-Ordonez1, Ahmed Ibrahim1, Ichiro Nakano1,3.   

Abstract

Glioblastoma (GBM), the most common primary malignant brain tumor in adults, is associated with significant morbidity and mortality despite maximal safe resection followed by chemo- and radiotherapy. GBMs contain self-renewing, tumorigenic glioma stem cells that contribute to tumor initiation, heterogeneity, therapeutic resistance, and recurrence. Intratumoral heterogeneity (ITH) of GBMs is also a major contributing factor to poor clinical outcomes associated with these high-grade glial tumors. Herein, the authors summarize recent discoveries and advances in the molecular and phenotypic characterization of GBMs with particular focus on ITH. In so doing, they attempt to highlight recent advances in molecular signatures/properties and metabolic alterations in an effort to clarify translational implications that may ultimately improve clinical outcomes.

Entities:  

Keywords:  CIMP+ = CIMP positive; CIMP− = CpG island methylator phenotype negative; EGFR = epidermal growth factor receptor; GBM; GBM = glioblastoma; GSC; GSC = glioma stem cell; IDH = isocitrate dehydrogenase; ITH = intratumoral heterogeneity; NSC = neural stem cell; SVZ = subventricular zone; experimental therapeutics; glioblastoma; glioma stem cells; intratumoral heterogeneity; oncology

Year:  2019        PMID: 31443071     DOI: 10.3171/2019.5.JNS19364

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.408


  23 in total

Review 1.  3D bioprinting of glioblastoma models.

Authors:  Carolina Parra-Cantu; Wanlu Li; Alfredo Quiñones-Hinojosa; Yu Shrike Zhang
Journal:  J 3D Print Med       Date:  2020-10-28

Review 2.  Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.

Authors:  Madison L Shoaf; Annick Desjardins
Journal:  Neurotherapeutics       Date:  2022-06-08       Impact factor: 7.620

Review 3.  Glutamine Imaging: A New Avenue for Glioma Management.

Authors:  S Ekici; J A Nye; S G Neill; J W Allen; H-K Shu; C C Fleischer
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-04       Impact factor: 3.825

4.  OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.

Authors:  Zhenhua Xu; Najiba Murad; Daniel Malawsky; Ran Tao; Samuel Rivero-Hinojosa; Dörthe Holdhof; Ulrich Schüller; Peng Zhang; Christopher Lazarski; Brian R Rood; Roger Packer; Timothy Gershon; Yanxin Pei
Journal:  Clin Cancer Res       Date:  2022-10-03       Impact factor: 13.801

5.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

6.  De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.

Authors:  Jack M Shireman; Fatemeh Atashi; Gina Lee; Eunus S Ali; Miranda R Saathoff; Cheol H Park; Sol Savchuk; Shivani Baisiwala; Jason Miska; Maciej S Lesniak; C David James; Roger Stupp; Priya Kumthekar; Craig M Horbinski; Issam Ben-Sahra; Atique U Ahmed
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

Review 7.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

Review 8.  The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.

Authors:  Joshua D Bernstock; Samantha E Hoffman; Jason A Chen; Saksham Gupta; Ari D Kappel; Timothy R Smith; E Antonio Chiocca
Journal:  Viruses       Date:  2021-06-17       Impact factor: 5.048

9.  Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.

Authors:  Pengfei Wu; Wei Yang; Jianxing Ma; Jingyu Zhang; Maojun Liao; Lunshan Xu; Minhui Xu; Liang Yi
Journal:  Oncol Lett       Date:  2019-10-11       Impact factor: 2.967

10.  A Comparison Study of Machine Learning (Random Survival Forest) and Classic Statistic (Cox Proportional Hazards) for Predicting Progression in High-Grade Glioma after Proton and Carbon Ion Radiotherapy.

Authors:  Xianxin Qiu; Jing Gao; Jing Yang; Jiyi Hu; Weixu Hu; Lin Kong; Jiade J Lu
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.